Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS®)

International Journal of Pharmaceutics

Volumn 263, Issue 1-2, 2003, Pages 51-60

  Fukui, Hiroshi ^a   Koike, Tomohiro ^a   Saheki, Akira ^a   Sonoke, Satoru ^a   Tomii, Yoshifumi ^a   Seki, Junzo ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

Amphotericin B; Lipid emulsion; LNS; Nanoemulsions

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; DEOXYCHOLATE SODIUM; DRUG VEHICLE; HIGH DENSITY LIPOPROTEIN; LIPID; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCULATION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; FUNGAL CELL; GEL PERMEATION CHROMATOGRAPHY; HEMOLYSIS; MALE; MAMMAL CELL; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY; TOXICOKINETICS;

EID: 0042383358     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00342-9     Document Type: Article

References (23)

1. Anaissie E., Paetznick V., Proffitt R., Adler-Moore J., Bodey G.P. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 10:1991;665-668.
2. Atkinson A.J., Bennett J.E. Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 13:1978;271-276.
3. Bekersky I., Fielding R.M., Dressler D.E., Lee J.W., Buell D.N., Walsh T.J. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46:2002;834-840.
4. Bolard J., Seigneuret M., Boudet G. Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: lipid state and cholesterol content dependence. Biochim. Biophys. Acta. 599:1980;280-293.
5. Brajtburg J., Elberg S., Bolard J., Kobayashi G.S., Levy R.A., Ostlund R.E., Schlessinger D., Medoff G. Interaction of plasma proteins and lipoproteins with amphotericin B. J. Infect. Dis. 149:1984;986-997.
6. Cushley R.J., Treleaven W.D., Parmar Y.I., Chana R.S., Fenske D.B. Surface diffusion in human serum lipoproteins. Biochem. Biophys. Res. Commun. 146:1987;1139-1145.
7. Egito E.S.T.D., Appel M., Fessi H., Barratt G., Puisieux F., Devissaguet J.P. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. J. Antimicrob. Chemother. 38:1996;485-497.
8. Forster D., Washington C., Davis S.S. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J. Pharm. Pharmacol. 40:1988;325-328.
9. Gallis H.A., Drew R.H., Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:1990;308-329.
10. Hillery A.M. Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv. Drug Deliv. Rev. 24:1997;345-363.
11. Jullien S., Brajtburg J., Bolard J. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations. Biochim. Biophys. Acta. 1021:1990;39-45.
12. Mehta R., Lopez-Berestein G., Hopfer R., Mills K., Juliano R.L. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim. Biophys. Acta. 770:1984;230-234.
13. Otsubo T., Maesaki S., Hossain M.A., Yamamoto Y., Tomono K., Tashiro T., Seki J., Tomii Y., Sonoke S., Kohno S. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphoteriocin B, against Aspergillus fumigatus. Antimicrob. Agents Chemother. 43:1999;471-475.
14. Pahls S., Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J. Infect. Dis. 169:1994;1057-1061.
15. Persson U., Tennvall G.R., Anderson S., Tyden G., Wettermark B. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. PharmacoEconomics. 2:1992;500-508.
16. Ralph E.D., Khazindar A.M., Barber K.R., Grant C.W.M. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob. Agents Chemother. 35:1991;188-191.
17. Seki J., Sasaki H., Doi M., Yoshikawa H., Takahashi Y., Yamane S., Fukui H., Sonoke S., Yamamoto H., Hirose M., Erure Y., Ando T., Ushimaru K., Sugiyama M. Lipid nano-sphere (LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration. IV. J. Controlled Release. 28:1994;352-353.
18. Shadkhan Y., Segal E., Bor A., Gov Y., Rubin M., Lichtenberg D. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J. Antimicrob. Chemother. 39:1997;655-658.
19. Wasan K.M., Brazeau G.A., Keyhani A., Hayman A.C., Lopez-Berestein G. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 37:1993;246-250.
20. Wasan K.M., Rosenblum M.G., Cheung L., Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 38:1994;223-227.
21. Washington C., Taylor S.J., Davis S.S. The structure of colloidal formulations of amphotericin B. Int. J. Pharm. 46:1988;25-30.
22. Witzke N.M., Bittman R. Dissociation kinetics and equilibrium binding properties of polyene antibiotic complexes with phosphatidylcholine/sterol vesicles. Biochemistry. 23:1984;1668-1674.
23. Wolford S.T., Schroer R.A., Gohs F.X., Gallo P.P., Brodeck M., Falk H.B., Ruhren R. Reference range data base for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environ. Health. 18:1986;161-188.